High affinity leptins and leptin antagonists

US8969292B2 · kind B2 · utility

Assignees

• The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center · IL
• YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. · IL

Inventors

• Arieh Gertler · Rehovot, IL
• Eran Elinav · Jerusalem, IL
• Zamir Halpern · Nes Ziona, IL

Key dates

• Filing date: Apr 17, 2011
• Grant date: Mar 3, 2015
• Expiry date: May 28, 2031

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A01K2217/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Leptin muteins, in particular leptin antagonists, with increased binding affinity to leptin receptor are provided. These compounds as well as pharmaceutical composition comprising them are useful for the treatment of any disorder in which a non-desirable or deleterious activity of endogenous leptin or an altered innate immune response is implicated.